Safety, Tolerability, and Adverse Event Management

This discussion addresses the safety and tolerability of first-line targeted therapies for EGFR-mutant NSCLC. Panelists outline the most common adverse effects, including dermatologic, gastrointestinal, and infusion-related reactions. They describe proactive strategies such as early symptom recognition, dose scheduling, and supportive care interventions that help mitigate toxicity and maintain adherence. Preventive measures from recent clinical studies are highlighted as effective in reducing the severity of treatment-related side adverse effects. The panel underscores that managing side adverse effects through multidisciplinary support allows patients to remain on therapy longer with a better quality of life.